PHILADELPHIA, Dec. 20, 2013 /PRNewswire/ -- Spark Therapeutics, a fully integrated, late-stage gene therapy company, announced today that President and Chief Executive Officer Jeffrey D. Marrazzo will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference. Marrazzo's presentation will highlight the company's progress in developing potentially curative, one-time gene therapies for the treatment of inherited blindness and hemophilia, and provide an overview of Spark's expertise and capabilities in the clinical development of adeno-associated virus (AAV) vectors. The presentation will take place at 1:30 PM PT on Tuesday, January 14, 2014 in the Elizabethan C room at the Westin St. Francis in San Francisco, California.

About Spark Therapeutics

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. Our robust pipeline includes a Phase 3 program in RPE65 blindness and a Phase 1/2 program in hemophilia B, as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has an unparalleled track record of success in supporting clinical studies across diverse therapeutic areas and routes of administration. The company's expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark's team while at The Children's Hospital of Philadelphia Center for Cellular and Molecular Therapeutics. To learn more visit www.sparktx.com.